E3 ubiquitin-protein ligase RNF220 (RNF220)

E3 ubiquitin-protein ligase RNF220 is an evolutionarily conserved RING-type enzyme that regulates protein stability and turnover through ubiquitination. It functions mainly in cellular signaling, neural development, and transcriptional regulation, targeting substrates such as β-catenin (promoting Wnt signaling), SIN3B (modulating chromatin condensation and spermatogenesis), AMPA receptors (controlling synaptic function and learning/memory), WDR5 (regulating Hox gene expression), and components of Sonic hedgehog signaling. RNF220 mutations are linked to neurodevelopmental diseases including leukodystrophy and intellectual disability, and its dysregulation is implicated in cancers (AML, colon cancer) and fertility disorders. RNF220 is widely expressed in the nervous system, localized in the nuclear lamina, and participates in protein complexes important for both normal development and disease[1][2][3][4][5][6][7].\n\nNo direct drug-target relationships are documented, but its multifaceted roles make RNF220 a candidate for future therapeutic intervention and biomarker development in oncology, neurodegeneration, and reproductive medicine[1][4][7].

Other names

C1orf164FLJ10597RING finger protein 220RING-type E3 ubiquitin transferase RNF220HLD23

For hypothetical drugs: Inhibition of E3 ligase activity (blocking ubiquitination of key substrates such as β-catenin, AMPA receptors, SIN3B, WDR5)\nRegulation of protein degradation pathways linked to cell cycle and neuronal activity[1][2][6]